Premium
Upregulation of the α‐secretase ADAM10 – risk or reason for hope?
Author(s) -
Endres Kristina,
Fahrenholz Falk
Publication year - 2010
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/j.1742-4658.2010.07566.x
Subject(s) - adam10 , disintegrin , metalloproteinase , amyloid precursor protein , amyloid precursor protein secretase , downregulation and upregulation , alpha secretase , protein precursor , alzheimer's disease , microbiology and biotechnology , matrix metalloproteinase , disease , cancer research , chemistry , neuroscience , biology , medicine , enzyme , biochemistry , gene
A decade ago, a disintegrin and metalloproteinase 10 (ADAM10) was identified as an α‐secretase and as a key proteinase in the processing of the amyloid precursor protein. Accordingly, the important role that it plays in Alzheimer’s disease was manifested. Animal models with an overexpression of ADAM10 revealed a beneficial profile of the metalloproteinase with respect to learning and memory, plaque load and synaptogenesis. Therefore, ADAM10 presents a worthwhile target with respect to the treatment of a neurodegenerative disease such as Morbus Alzheimer. Initially, ADAM10 was suggested to be an enzyme, shaping the extracellular matrix by cleavage of collagen type IV, or to be a tumour necrosis factor α convertase. In a relatively short time, a wide variety of additional substrates (with amyloid precursor protein probably being the most prominent) has been identified and the search is still ongoing. Hence, any side effects concerning the therapeutic enhancement of ADAM10 α‐secretase activity have to be considered. The present review summarizes our knowledge about the structure and function of ADAM10 and highlights the opportunities for enhancing the expression and/or activity of the α‐secretase as a therapeutic target.